Epizyme Inc ((EPZM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Epizyme Inc. is conducting a Phase I study titled ‘A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies.’ The study aims to evaluate the pharmacokinetics and safety of tazemetostat, a drug for advanced cancer patients with varying liver function, to understand its effects and tolerability.
The intervention being tested is tazemetostat, an oral drug administered in 800 mg doses. It is designed to treat advanced malignancies, particularly in patients with liver impairments, by inhibiting cancer cell growth.
The study is interventional, with a single-group assignment and no masking, focusing on treatment. This straightforward design allows researchers to directly observe the effects of tazemetostat on the participants.
The study began on January 15, 2020, and the last update was submitted on July 31, 2025. These dates are crucial for tracking the study’s progress and ensuring up-to-date information is available for stakeholders.
This update could influence Epizyme Inc.’s stock performance positively, as successful results may enhance investor confidence and market position. Competitors in the oncology sector will be closely monitoring these developments, given the potential impact on treatment options for liver-impaired cancer patients.
The study is ongoing, and further details are accessible on the ClinicalTrials portal.